26.94
전일 마감가:
$26.66
열려 있는:
$26.81
하루 거래량:
1.24M
Relative Volume:
0.71
시가총액:
$4.44B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
13.81
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
-6.71%
1개월 성능:
-7.48%
6개월 성능:
-10.91%
1년 성능:
+8.52%
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ALKS
Alkermes Plc
|
26.95 | 4.90B | 1.51B | 333.35M | 315.22M | 1.95 |
![]()
ZTS
Zoetis Inc
|
149.31 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.60 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.19 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.62 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-15 | 개시 | Goldman | Buy |
2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
2025-05-28 | 개시 | Needham | Buy |
2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
2025-02-11 | 개시 | Deutsche Bank | Buy |
2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
2024-06-17 | 개시 | TD Cowen | Buy |
2024-03-19 | 개시 | Robert W. Baird | Outperform |
2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
2023-11-20 | 재개 | JP Morgan | Neutral |
2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
2023-10-17 | 개시 | UBS | Neutral |
2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
2022-08-16 | 개시 | Piper Sandler | Neutral |
2022-04-22 | 재개 | Goldman | Buy |
2022-04-20 | 개시 | Goldman | Buy |
2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
2021-12-01 | 개시 | Citigroup | Neutral |
2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-02-06 | 개시 | Mizuho | Neutral |
2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
2019-05-31 | 개시 | H.C. Wainwright | Neutral |
2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
2018-12-14 | 개시 | Wolfe Research | Underperform |
2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
2018-11-05 | 개시 | Piper Jaffray | Neutral |
2018-08-07 | 개시 | Stifel | Hold |
2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - TradingView
Is Alkermes plc a good long term investmentPhenomenal returns - jammulinksnews.com
What drives Alkermes plc stock priceFree Consultation - Autocar Professional
What analysts say about Alkermes plc stockOutstanding capital returns - Autocar Professional
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - Yahoo Finance
Alkermes Announces Positive Phase 2 Study Results - TipRanks
Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl
Why Is Alkermes Stock Falling On Monday?Alkermes (NASDAQ:ALKS) - Benzinga
Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive
Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK
Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq
Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener
Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire
Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛
Alkermes plc Stock Analysis and ForecastRecord-breaking capital gains - Autocar Professional
10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN
BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India
BlackRock increases stake in Alkermes to 17.05% - Investing.com
Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest
Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener
Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga
Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years - simplywall.st
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance
Alkermes plc(NasdaqGS: ALKS) added to Russell 2500 Value Index - MarketScreener
Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN
(ALKS) On The My Stocks Page - news.stocktradersdaily.com
Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize
Alkermes (ALKS) Upgraded by UBS with Positive Development Prospe - GuruFocus
Alkermes stock upgraded at UBS on sleep disorder drug (ALKS) - Seeking Alpha
Alkermes' ALKS-2680 Seen as Potential Breakthrough for Narcolepsy, Hypersomnia, BofA Says - MarketScreener
Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | A - GuruFocus
Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | ALKS Stock News - GuruFocus
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stoc - GuruFocus
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga
Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stock News - GuruFocus
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33 - marketscreener.com
Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narco - GuruFocus
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alkermes Plc 주식 (ALKS) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Nichols Christian Todd | SVP, Chief Commercial Officer |
Jun 10 '25 |
Sale |
31.09 |
3,334 |
103,654 |
86,208 |
자본화:
|
볼륨(24시간):